We’re pleased to attend the Yale Innovation Summit from May 27th - 28th. With over 2,800 attendees, this is the largest innovation gathering in the Northeast. The Biotech Track will feature stimulating panels and exciting venture showcases. Join us in exploring the latest innovations that are shaping the future of licensing, diagnostics and therapeutics.
What is the Yale Innovation Summit?
The Yale Innovation Summit is a reflection of Yale’s entrepreneurial momentum in arts, biotech, civic, climate, health, and tech. It’s where ideas are transformed into real world impact. This is a fantastic opportunity to connect with the next generation of startups and network with key opinion leaders.
Event Overview
Date: May 27th - 28th, 2026
Venue: Yale School of Management, 165 Whitney Ave, New Haven, CT 06511
Event Schedule
For more information, please refer to the event schedule.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in New Haven, CT!
